Haemonetics Corporation
Health
Performance
5.7
Risk
Sell
Buy
Curious about the Scores? Learn more.

Haemonetics Corporation stock rating and score history

All changes in ratings, performance and outlook tracked over time.

25.08.2026
Sliding into average ground. Desperately needs a real boost.
19.08.2026
Picking up speed. Momentum turning positive.
16.07.2026
Signs of control returning. Still shaky, but not chaos.
12.07.2026
Health’s picking up. Numbers look cleaner, cash flow tighter.
HAE
Haemonetics Corporation
102.92
+0.07%
5.7
Sell
Buy
Haemonetics Corporation

Haemonetics Corporation stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Haemonetics Corporation do? Business model and key facts

Get the full picture of Haemonetics Corporation: what it builds, where it operates, and how it makes money.

Haemonetics Corporation Profile

Sector: Healthcare

Industry: Medical - Devices

Employees (FY): 3009

Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.

shop
Company facts
Christopher A. Simon
CEO
3009
Employees worldwide
shop
Performance
89.26%
Last 12 months
59.59%
Last 5 years
shop
Growth
$1.33B
Revenue year
$97.31M
Net income
shop
Valuation
$4.68B
Market Cap
26.36
Price/Earnings Ratio

Stocks related to Haemonetics Corporation

Selected based on industry alignment and relative market positioning.

BRKR
Bruker Corporation
58.50
-1.53%
6.5
Sell
Buy
Bruker Corporation
MASI
Masimo Corporation
179.95
+0.00%
4.7
Sell
Buy
Masimo Corporation
PODD
Insulet Corp.
147.48
-2.06%
6.8
Sell
Buy
Insulet Corp.
LIVN
LivaNova PLC
81.92
+0.89%
3.4
Sell
Buy
LivaNova PLC
ITGR
Integer Holdings Corporation
126.50
+0.80%
6.2
Sell
Buy
Integer Holdings Corporation

Events and news impacting Haemonetics Corporation stock

Earnings, coporate decisions and industry developments that can affect the share price.

Haemonetics Corporation fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.